Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 965

1.

Never tear us a-PARP: Dealing with DNA lesions during mitosis.

Schoonen PM, van Vugt MATM.

Mol Cell Oncol. 2017 Oct 31;5(1):e1382670. doi: 10.1080/23723556.2017.1382670. eCollection 2018.

PMID:
29404385
2.

Discovering drugs to overcome chemoresistance in ovarian cancers based on the cancer genome atlas tumor transcriptome profile.

Wang F, Chang JT, Zhang Z, Morrison G, Nath A, Bhutra S, Huang RS.

Oncotarget. 2017 Dec 4;8(70):115102-115113. doi: 10.18632/oncotarget.22870. eCollection 2017 Dec 29.

3.

A game of substrates: replication fork remodeling and its roles in genome stability and chemo-resistance.

Sidorova J.

Cell Stress. 2017 Dec;1(3):115-133. doi: 10.15698/cst2017.12.114. Epub 2017 Dec 5.

4.

Loss of NEIL3 DNA glycosylase markedly increases replication associated double strand breaks and enhances sensitivity to ATR inhibitor in glioblastoma cells.

Klattenhoff AW, Thakur M, Chu CS, Ray D, Habib SL, Kidane D.

Oncotarget. 2017 Dec 4;8(68):112942-112958. doi: 10.18632/oncotarget.22896. eCollection 2017 Dec 22.

5.

Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing.

Yang H, Jaeger M, Walker A, Wei D, Leiker K, Weitao T.

J Cancer. 2018 Jan 1;9(2):219-231. doi: 10.7150/jca.22554. eCollection 2018. Review.

6.

Target engagement imaging of PARP inhibitors in small-cell lung cancer.

Carney B, Kossatz S, Lok BH, Schneeberger V, Gangangari KK, Pillarsetty NVK, Weber WA, Rudin CM, Poirier JT, Reiner T.

Nat Commun. 2018 Jan 12;9(1):176. doi: 10.1038/s41467-017-02096-w.

7.

Proteomic Analysis of the Downstream Signaling Network of PARP1.

Zhen Y, Yu Y.

Biochemistry. 2018 Jan 30;57(4):429-440. doi: 10.1021/acs.biochem.7b01022. Epub 2018 Jan 19.

PMID:
29327913
8.

Dualistic Role of BARD1 in Cancer.

Cimmino F, Formicola D, Capasso M.

Genes (Basel). 2017 Dec 8;8(12). pii: E375. doi: 10.3390/genes8120375. Review.

9.

Emerging treatment options for ovarian cancer: focus on rucaparib.

Mariappan L, Jiang XY, Jackson J, Drew Y.

Int J Womens Health. 2017 Dec 15;9:913-924. doi: 10.2147/IJWH.S151194. eCollection 2017. Review.

10.

The Role of Chromosomal Instability in Cancer and Therapeutic Responses.

Vargas-Rondón N, Villegas VE, Rondón-Lagos M.

Cancers (Basel). 2017 Dec 28;10(1). pii: E4. doi: 10.3390/cancers10010004. Review.

11.

High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy.

Perez-Lopez R, Roda D, Jimenez B, Brown J, Mateo J, Carreira S, Lopez J, Banerji U, Molife LR, Koh DM, Kaye SB, de Bono JS, Tunariu N, Yap TA.

Oncotarget. 2017 Nov 6;8(61):104430-104443. doi: 10.18632/oncotarget.22303. eCollection 2017 Nov 28.

12.

PARP inhibition causes premature loss of cohesion in cancer cells.

Kukolj E, Kaufmann T, Dick AE, Zeillinger R, Gerlich DW, Slade D.

Oncotarget. 2017 Oct 16;8(61):103931-103951. doi: 10.18632/oncotarget.21879. eCollection 2017 Nov 28.

13.

Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer.

Ratajska M, Koczkowska M, Żuk M, Gorczyński A, Kuźniacka A, Stukan M, Biernat W, Limon J, Wasąg B.

Oncotarget. 2017 Sep 8;8(60):101325-101332. doi: 10.18632/oncotarget.20722. eCollection 2017 Nov 24.

14.

BRCA mutations in the manifestation and treatment of ovarian cancer.

Pan Z, Xie X.

Oncotarget. 2017 May 30;8(57):97657-97670. doi: 10.18632/oncotarget.18280. eCollection 2017 Nov 14. Review.

15.

Boosting the effects of hyperthermia-based anticancer treatments by HSP90 inhibition.

Vriend LEM, van den Tempel N, Oei AL, L'Acosta M, Pieterson FJ, Franken NAP, Kanaar R, Krawczyk PM.

Oncotarget. 2017 Oct 27;8(57):97490-97503. doi: 10.18632/oncotarget.22142. eCollection 2017 Nov 14.

16.

Protein phosphatase 4 regulatory subunit 2 (PPP4R2) is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair.

Herzig JK, Bullinger L, Tasdogan A, Zimmermann P, Schlegel M, Teleanu V, Weber D, Rücker FG, Paschka P, Dolnik A, Schneider E, Kuchenbauer F, Heidel FH, Buske C, Döhner H, Döhner K, Gaidzik VI.

Oncotarget. 2017 Sep 21;8(56):95038-95053. doi: 10.18632/oncotarget.21119. eCollection 2017 Nov 10.

17.

PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.

Sisay M, Edessa D.

Gynecol Oncol Res Pract. 2017 Nov 29;4:18. doi: 10.1186/s40661-017-0055-8. eCollection 2017. Review.

18.

RBR-type E3 ubiquitin ligase RNF144A targets PARP1 for ubiquitin-dependent degradation and regulates PARP inhibitor sensitivity in breast cancer cells.

Zhang Y, Liao XH, Xie HY, Shao ZM, Li DQ.

Oncotarget. 2017 Oct 10;8(55):94505-94518. doi: 10.18632/oncotarget.21784. eCollection 2017 Nov 7.

19.

Hypersensitivity of BRCA2 deficient cells to rosemary extract explained by weak PARP inhibitory activity.

Su C, Gius JP, Van Steenberg J, Haskins AH, Heishima K, Omata C, Iwayama M, Murakami M, Mori T, Maruo K, Kato TA.

Sci Rep. 2017 Dec 1;7(1):16704. doi: 10.1038/s41598-017-16795-3.

20.

Acetylation of 53BP1 dictates the DNA double strand break repair pathway.

Guo X, Bai Y, Zhao M, Zhou M, Shen Q, Yun CH, Zhang H, Zhu WG, Wang J.

Nucleic Acids Res. 2018 Jan 25;46(2):689-703. doi: 10.1093/nar/gkx1208.

Supplemental Content

Support Center